메뉴 건너뛰기




Volumn 102, Issue 1, 2011, Pages 137-143

Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANDESARTAN HEXETIL; CIMETIDINE; MELOXICAM; PERINDOPRIL;

EID: 78650202092     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01756.x     Document Type: Article
Times cited : (35)

References (43)
  • 2
    • 41849123889 scopus 로고    scopus 로고
    • Establishing the role of cytokine therapy in advanced renal cell carcinoma
    • Gore ME, De Mulder P. Establishing the role of cytokine therapy in advanced renal cell carcinoma. BJU Int 2008; 101: 1063-70.
    • (2008) BJU Int , vol.101 , pp. 1063-1070
    • Gore, M.E.1    De Mulder, P.2
  • 4
    • 33748569461 scopus 로고    scopus 로고
    • Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
    • Vogl UM, Zehetgruber H, Dominkus M et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 2006; 95: 691-8.
    • (2006) Br J Cancer , vol.95 , pp. 691-698
    • Vogl, U.M.1    Zehetgruber, H.2    Dominkus, M.3
  • 5
    • 4644335916 scopus 로고    scopus 로고
    • Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma
    • Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004; 10: 6342S-6S.
    • (2004) Clin Cancer Res , vol.10
    • Atkins, M.B.1    Regan, M.2    McDermott, D.3
  • 7
    • 76749116183 scopus 로고    scopus 로고
    • Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
    • Gore ME, Griffin CL, Hancock B et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010; 375: 641-8.
    • (2010) Lancet , vol.375 , pp. 641-648
    • Gore, M.E.1    Griffin, C.L.2    Hancock, B.3
  • 8
    • 0036138580 scopus 로고    scopus 로고
    • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    • Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96.
    • (2002) J Clin Oncol , vol.20 , pp. 289-296
    • Motzer, R.J.1    Bacik, J.2    Murphy, B.A.3    Russo, P.4    Mazumdar, M.5
  • 9
    • 0032471712 scopus 로고    scopus 로고
    • Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response
    • Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228: 307-19.
    • (1998) Ann Surg , vol.228 , pp. 307-319
    • Rosenberg, S.A.1    Yang, J.C.2    White, D.E.3    Steinberg, S.M.4
  • 10
    • 33846200478 scopus 로고    scopus 로고
    • Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents
    • Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 2007; 99: 274-80.
    • (2007) BJU Int , vol.99 , pp. 274-280
    • Bellmunt, J.1    Montagut, C.2    Albiol, S.3    Carles, J.4    Maroto, P.5    Orsola, A.6
  • 11
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 12
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90.
    • (2009) J Clin Oncol , vol.27 , pp. 3584-3590
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 13
    • 37349080670 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    • Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11.
    • (2007) Lancet , vol.370 , pp. 2103-2111
    • Escudier, B.1    Pluzanska, A.2    Koralewski, P.3
  • 14
    • 56749161699 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
    • Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8.
    • (2008) J Clin Oncol , vol.26 , pp. 5422-5428
    • Rini, B.I.1    Halabi, S.2    Rosenberg, J.E.3
  • 15
    • 34248345563 scopus 로고    scopus 로고
    • The renin angiotensin system in the regulation of angiogenesis
    • Heffelfinger SC. The renin angiotensin system in the regulation of angiogenesis. Curr Pharm Des 2007; 13: 1215-29.
    • (2007) Curr Pharm Des , vol.13 , pp. 1215-1229
    • Heffelfinger, S.C.1
  • 16
    • 0026577981 scopus 로고
    • High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study
    • Inhorn L, Williams SD, Nattam S, Stephens D. High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study. Am J Clin Oncol 1992; 15: 157-9.
    • (1992) Am J Clin Oncol , vol.15 , pp. 157-159
    • Inhorn, L.1    Williams, S.D.2    Nattam, S.3    Stephens, D.4
  • 17
    • 33644859805 scopus 로고    scopus 로고
    • Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review)
    • Lefranc F, Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review). Int J Oncol 2006; 28: 1021-30.
    • (2006) Int J Oncol , vol.28 , pp. 1021-1030
    • Lefranc, F.1    Yeaton, P.2    Brotchi, J.3    Kiss, R.4
  • 18
    • 0036681694 scopus 로고    scopus 로고
    • Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis
    • Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002; 62: 4176-9.
    • (2002) Cancer Res , vol.62 , pp. 4176-4179
    • Miyajima, A.1    Kosaka, T.2    Asano, T.3    Seta, K.4    Kawai, T.5    Hayakawa, M.6
  • 19
    • 31544455868 scopus 로고    scopus 로고
    • Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
    • Rini BI, Weinberg V, Dunlap S et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006; 106: 566-75.
    • (2006) Cancer , vol.106 , pp. 566-575
    • Rini, B.I.1    Weinberg, V.2    Dunlap, S.3
  • 20
    • 70449333312 scopus 로고    scopus 로고
    • Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma
    • Shinohara N, Kumagai A, Kanagawa K et al. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jpn J Clin Oncol 2009; 39: 720-6.
    • (2009) Jpn J Clin Oncol , vol.39 , pp. 720-726
    • Shinohara, N.1    Kumagai, A.2    Kanagawa, K.3
  • 21
    • 37849053338 scopus 로고    scopus 로고
    • Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment
    • Uemura H, Ishiguro H, Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 2008; 15: 19-26.
    • (2008) Int J Urol , vol.15 , pp. 19-26
    • Uemura, H.1    Ishiguro, H.2    Kubota, Y.3
  • 22
    • 51349138395 scopus 로고    scopus 로고
    • Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: report of three cases
    • Tatokoro M, Fujii Y, Kawakami S et al. Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: report of three cases. Int J Urol 2008; 15: 848-50.
    • (2008) Int J Urol , vol.15 , pp. 848-850
    • Tatokoro, M.1    Fujii, Y.2    Kawakami, S.3
  • 24
    • 33745319059 scopus 로고    scopus 로고
    • Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis
    • Kinouchi T, Sakamoto J, Tsukamoto T et al. Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis. J Cancer Res Clin Oncol 2006; 132: 499-504.
    • (2006) J Cancer Res Clin Oncol , vol.132 , pp. 499-504
    • Kinouchi, T.1    Sakamoto, J.2    Tsukamoto, T.3
  • 25
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 26
    • 65949102289 scopus 로고    scopus 로고
    • Immunotherapy of metastatic renal cell carcinoma
    • McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009; 115: 2298-305.
    • (2009) Cancer , vol.115 , pp. 2298-2305
    • McDermott, D.F.1
  • 28
    • 0347995046 scopus 로고    scopus 로고
    • Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis
    • Noguchi R, Yoshiji H, Kuriyama S et al. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 2003; 9: 6038-45.
    • (2003) Clin Cancer Res , vol.9 , pp. 6038-6045
    • Noguchi, R.1    Yoshiji, H.2    Kuriyama, S.3
  • 29
    • 69049113864 scopus 로고    scopus 로고
    • Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy
    • Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 2009; 135: 1429-35.
    • (2009) J Cancer Res Clin Oncol , vol.135 , pp. 1429-1435
    • Wilop, S.1    von Hobe, S.2    Crysandt, M.3    Esser, A.4    Osieka, R.5    Jost, E.6
  • 30
    • 0030970053 scopus 로고    scopus 로고
    • Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine
    • Kinouchi T, Saiki S, Maeda O, Kuroda M, Usami M, Kotake T. Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine. J Urol 1997; 157: 1604-7.
    • (1997) J Urol , vol.157 , pp. 1604-1607
    • Kinouchi, T.1    Saiki, S.2    Maeda, O.3    Kuroda, M.4    Usami, M.5    Kotake, T.6
  • 31
    • 15444365932 scopus 로고    scopus 로고
    • Cancer, inflammation and the AT1 and AT2 receptors
    • Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond) 2004; 1: 3.
    • (2004) J Inflamm (Lond) , vol.1 , pp. 3
    • Smith, G.R.1    Missailidis, S.2
  • 32
    • 48749092867 scopus 로고    scopus 로고
    • First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma
    • Melichar B, Koralewski P, Ravaud A et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-6.
    • (2008) Ann Oncol , vol.19 , pp. 1470-1476
    • Melichar, B.1    Koralewski, P.2    Ravaud, A.3
  • 33
  • 34
    • 70249097380 scopus 로고    scopus 로고
    • Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    • Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-8.
    • (2009) J Clin Oncol , vol.27 , pp. 3312-3318
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 35
    • 73349084973 scopus 로고    scopus 로고
    • Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
    • Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9.
    • (2009) J Clin Oncol , vol.27 , pp. 5794-5799
    • Heng, D.Y.1    Xie, W.2    Regan, M.M.3
  • 36
    • 0037163481 scopus 로고    scopus 로고
    • Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study
    • Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002; 162: 1985-93.
    • (2002) Arch Intern Med , vol.162 , pp. 1985-1993
    • Clegg, L.X.1    Li, F.P.2    Hankey, B.F.3    Chu, K.4    Edwards, B.K.5
  • 37
    • 34548715340 scopus 로고    scopus 로고
    • Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004
    • Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK. Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004. Cancer 2007; 110: 1255-63.
    • (2007) Cancer , vol.110 , pp. 1255-1263
    • Robbins, A.S.1    Koppie, T.M.2    Gomez, S.L.3    Parikh-Patel, A.4    Mills, P.K.5
  • 38
    • 44149124558 scopus 로고    scopus 로고
    • Impact of gender in renal cell carcinoma: an analysis of the SEER database
    • Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 2008; 54: 133-40.
    • (2008) Eur Urol , vol.54 , pp. 133-140
    • Aron, M.1    Nguyen, M.M.2    Stein, R.J.3    Gill, I.S.4
  • 39
    • 72149129759 scopus 로고    scopus 로고
    • Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients
    • Naito S, Yamamoto N, Takayama T et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010; 57: 317-25.
    • (2010) Eur Urol , vol.57 , pp. 317-325
    • Naito, S.1    Yamamoto, N.2    Takayama, T.3
  • 40
    • 4644324025 scopus 로고    scopus 로고
    • Cancer immunotherapy: moving beyond current vaccines
    • Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
    • (2004) Nat Med , vol.10 , pp. 909-915
    • Rosenberg, S.A.1    Yang, J.C.2    Restifo, N.P.3
  • 41
    • 77649330490 scopus 로고    scopus 로고
    • Learning from cancer: the adaptive growth, wound and immune responses
    • Smith GR, Missailidis S. Learning from cancer: the adaptive growth, wound and immune responses. Gene Ther Mol Biol 2009; 13: 158-85.
    • (2009) Gene Ther Mol Biol , vol.13 , pp. 158-185
    • Smith, G.R.1    Missailidis, S.2
  • 42
    • 34247628373 scopus 로고    scopus 로고
    • Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma
    • Recchia F, Saggio G, Amiconi G et al. Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma. J Immunother 2007; 30: 448-54.
    • (2007) J Immunother , vol.30 , pp. 448-454
    • Recchia, F.1    Saggio, G.2    Amiconi, G.3
  • 43
    • 33644832319 scopus 로고    scopus 로고
    • Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer
    • Recchia F, Saggio G, Nuzzo A et al. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer. J Immunother 2006; 29: 87-94.
    • (2006) J Immunother , vol.29 , pp. 87-94
    • Recchia, F.1    Saggio, G.2    Nuzzo, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.